OncLive TV

Dr. Overman on Implications of Tumor Location Data for Patients With mCRC

July 11th 2016

Michael J. Overman, MD, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses how the results of the phase III FIRE-3 and 80405 studies will impact treatment of patients with metastatic colorectal cancer.

Dr. Loppenberg on Benefits of Local Treatment for Metastatic Prostate Cancer

July 11th 2016

Dr. Howard Burris on Patient-Reported Outcomes of MARIANNE

July 9th 2016

Dr. Jonathan Trent on Engineered T- cell Therapy in Sarcoma

July 9th 2016

Dr. Saad on Patients With mCRPC Eligible for 6-Doses of Radium-223

July 8th 2016

Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).

Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

July 8th 2016

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia.

Dr. Ryan Sullivan on Treatment Options for Advanced Basal Cell Carcinoma

July 8th 2016

Dr. Jorge Garcia on METEOR Trial for RCC

July 7th 2016

Jorge A. Garcia, MD, Department of Hematology and Oncology, discusses the results of the phase III METEOR trial, which compared the efficacy of cabozantinib (Cabometyx) versus everolimus (Afinitor) in patients with advanced renal cell carcinoma.

Dr. Esteva on Trastuzumab Biosimilar in Patients With HER2+ Breast Cancer

July 7th 2016

Francisco J. Esteva, MD, PhD, medical oncology, New York Langone Medical Center, discusses a phase III study of the biosimilar version of trastuzumab (Herceptin) in patients with HER2-positive metastatic breast cancer.

Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma

July 7th 2016

​Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

Dr. Nanus on Next Steps With Atezolizumab in Patients With mUC

July 7th 2016

David M. Nanus, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the unanswered questions that remain with atezolizumab (Tecentriq) in patients with metastatic urothelial carcinoma (mUC).

Dr. Francesco Forconi on B-cell Receptor Structure and Function in CLL

July 6th 2016

Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses the role of the B-cell receptor (BCR) in chronic lymphocytic leukemia (CLL).

Dr. Kurian on Association of Ovarian Cancer Risk With Mutations Detected by Multiple-Gene Germline Sequencing

July 6th 2016

Allison W. Kurian, MD, MSc, associate professor of Medicine and of Health Research and Policy, Stanford University School of Medicine, discusses an ongoing trial exploring the association of ovarian cancer risk with mutations detected by multiple-gene germline sequencing in 95,561 women.

Dr. Keith Kerr on Selecting Patients for Immunotherapy in Lung Cancer

July 6th 2016

Dr. Churilla on Impact of Health Insurance Status on Patients With HNSCC

July 5th 2016

Thomas M. Churilla, MD, Department of Radiation Oncology, Fox Chase Cancer Center, discusses a study exploring the impact of health insurance status on the presentation, local management, and outcomes of patients with head and neck cancer.

Dr. Bauer on Rovalpituzumab Tesirine in Patients With SCLC

July 5th 2016

Todd Bauer, MD, associate director, Drug Development, principal investigator, Sarah Cannon Research Institute, discusses the safety and efficacy of single-agent rovalpituzumab tesirine (Rova-T), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate in recurrent/refractory patients with small cell lung cancer (SCLC).

Dr. Pieter Sonneveld on a Prognostic Indicator for Multiple Myeloma

July 5th 2016

Dr. Berger on the Significance of the Cologuard Screening Test

July 1st 2016

Barry M. Berger, MD, FACP, chief medical officer, Exact Sciences, discusses the significance and benefits of the Cologuard screening test for colorectal cancer.

Dr. Kuerer on Challenges With Treating DCIS

June 30th 2016

Henry M. Kuerer, MD, PhD, professor of Surgery, PH and Fay Etta Robinson Distinguished Professor in Research, Breast Surgical Oncology, executive director, Breast Programs, director, Breast Surgical Oncology Fellowship Training Program, Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the challenges associated with treating patients with ductal carcinoma in situ (DCIS).

Dr. Shaji Kumar on Novel Frontline Treatment Options in Multiple Myeloma

June 30th 2016